In fact, the most frequent molecular alterations identified in glioma and glioblastoma patients (CDKN2A/2B, PTEN, TP53, TERT, PIK3CA/B and EGFR alterations) have no clinically active drugs for treatment of CNS tumors. The gene discussed is TP53; the disease is central nervous system cancer.